CAMP
CAMP4 THERAPEUTICS CORPORATION
Price Chart
Latest Quote
$4.13
-0.01 (-0.24%)
Current Price
| Previous Close | $4.14 |
| Open | $4.29 |
| Day High | $4.45 |
| Day Low | $3.92 |
| Volume | 158,789 |
Stock Information
| Shares Outstanding | 51.93M |
| Total Debt | $2.12M |
| Cash Equivalents | $99.21M |
| Revenue | $3.93M |
| Net Income | $-86.30M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $214.45M |
| EPS (TTM) | $-2.35 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $117.37M |
| Sales | $3.93M |
| Income | $-86.30M |
| Book/sh | $0.59 |
| Cash/sh | $1.91 |
| Employees | 48 |
Financial Ratios
| Quick Ratio | 5.97 |
| Current Ratio | 6.15 |
| Debt/Eq | 6.87 |
Returns & Margins
| ROA | -38.66% |
| ROE | -209.28% |
| Operating Margin | -1010.12% |
Ownership
| Insider Ownership | 13.07% |
| Institutional Ownership | 86.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.30 |
| P/S | 54.51 |
| P/B | 6.94 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.58 |
Technical Indicators
| SMA20 | $4.20 |
| SMA50 | $4.30 |
| SMA200 | $4.25 |
| RSI | 43.23 |
| ATR | 0.4925 |
| Shares Float | 26.50M |
| Short Float | 0.97% |
| Short Ratio | 4.36 |
| Rel Volume | 1.27 |
Performance History
| Week | -2.13% |
| Month | -0.48% |
| Quarter | -19.96% |
| 6 Months | -41.08% |
| YTD | -31.17% |
| Year | +197.12% |
| 10 Years | -61.47% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.13 | 161,100 |
| 2026-06-17 | $4.14 | 197,500 |
| 2026-06-16 | $4.13 | 867,200 |
| 2026-06-15 | $3.96 | 88,400 |
| 2026-06-12 | $4.19 | 41,000 |
| 2026-06-11 | $4.22 | 60,200 |
| 2026-06-10 | $4.34 | 181,200 |
| 2026-06-09 | $4.01 | 60,000 |
| 2026-06-08 | $4.09 | 77,800 |
| 2026-06-05 | $4.11 | 68,800 |
| 2026-06-04 | $4.30 | 61,900 |
| 2026-06-03 | $4.17 | 48,400 |
| 2026-06-02 | $3.98 | 88,500 |
| 2026-06-01 | $4.04 | 81,800 |
| 2026-05-29 | $4.39 | 50,900 |
| 2026-05-28 | $4.49 | 93,700 |
| 2026-05-27 | $4.21 | 63,900 |
| 2026-05-26 | $4.10 | 113,000 |
| 2026-05-22 | $4.51 | 76,200 |
| 2026-05-21 | $4.40 | 60,700 |
| 2026-05-20 | $4.50 | 31,400 |
| 2026-05-19 | $4.15 | 47,300 |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation
Simply Wall St. âĸ 2026-06-06T12:57:46Z
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T23:05:18Z
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H
MarketBeat âĸ 2026-04-13T17:36:02Z
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Motley Fool âĸ 2026-03-18T18:08:40Z
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
Motley Fool âĸ 2026-03-18T17:54:46Z
Biotech Alert: Searches spiking for these stocks today
TipRanks âĸ 2026-03-12T16:25:40Z
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why
Zacks âĸ 2026-01-13T17:00:03Z
Novo files for CagriSema approval; Merck and Pfizerâs trial win
BioPharma Dive âĸ 2025-12-19T11:01:21Z
Positive week for Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional investors who lost 46% over the past year
Simply Wall St. âĸ 2025-12-10T10:36:05Z
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-09-25T16:00:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $3,498,000 | $652,000 | $350,000 | $0 |
| Operating Revenue | $3,498,000 | $652,000 | $350,000 | $0 |
| Expenses | ||||
| Total Expenses | $55,559,000 | $53,740,000 | $52,229,000 | $45,001,000 |
| Other Income Expense | $-30,516,000 | $-33,000 | $-220,000 | $-95,000 |
| Other Non Operating Income Expenses | $-192,000 | $-33,000 | $-220,000 | $-95,000 |
| Net Non Operating Interest Income Expense | $2,174,000 | $1,330,000 | $2,808,000 | $904,000 |
| Operating Expense | $55,559,000 | $53,740,000 | $52,229,000 | $45,001,000 |
| General And Administrative Expense | $17,357,000 | $14,923,000 | $11,613,000 | $10,230,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Net Interest Income | $2,174,000 | $1,330,000 | $2,808,000 | $904,000 |
| Interest Income | $2,174,000 | $1,330,000 | $2,808,000 | $904,000 |
| Normalized Income | $-50,079,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Net Income From Continuing And Discontinued Operation | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Total Operating Income As Reported | $-52,555,000 | $-53,088,000 | $-51,879,000 | $-45,001,000 |
| Net Income Common Stockholders | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Net Income | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Net Income Including Noncontrolling Interests | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Net Income Continuous Operations | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Pretax Income | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Special Income Charges | $-494,000 | $0 | - | - |
| Interest Income Non Operating | $2,174,000 | $1,330,000 | $2,808,000 | $904,000 |
| Operating Income | $-52,061,000 | $-53,088,000 | $-51,879,000 | $-45,001,000 |
| Per Share | ||||
| Diluted EPS | $-2.65 | $-11.04 | $-4.07 | $-3.64 |
| Basic EPS | $-2.65 | $-11.04 | $-4.07 | $-3.64 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-20,098,000 | $-51,392,000 | $-50,201,000 | $-44,123,000 |
| Total Unusual Items | $-30,324,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-30,324,000 | $0 | - | - |
| Reconciled Depreciation | $1,639,000 | $1,696,000 | $1,678,000 | $878,000 |
| EBITDA (Bullshit earnings) | $-50,422,000 | $-51,392,000 | $-50,201,000 | $-44,123,000 |
| EBIT | $-52,061,000 | $-53,088,000 | $-51,879,000 | $-45,001,000 |
| Diluted Average Shares | $30,380,567 | $4,690,094 | $12,124,749 | $12,124,749 |
| Basic Average Shares | $30,380,567 | $4,690,094 | $12,124,749 | $12,124,749 |
| Diluted NI Availto Com Stockholders | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
| Impairment Of Capital Assets | $494,000 | $0 | - | - |
| Gain On Sale Of Security | $-29,830,000 | - | - | - |
| Research And Development | $38,202,000 | $38,817,000 | $40,616,000 | $34,771,000 |
| Selling General And Administration | $17,357,000 | $14,923,000 | $11,613,000 | $10,230,000 |
| Other Gand A | $9,006,000 | $6,558,000 | $11,613,000 | $4,852,000 |
| Salaries And Wages | $8,351,000 | $8,365,000 | $6,909,000 | $5,378,000 |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Total Assets | $117,808,000 | $78,307,000 | $54,946,000 | $102,549,000 |
| Total Non Current Assets | $3,713,000 | $11,924,000 | $14,933,000 | $18,141,000 |
| Other Non Current Assets | $894,000 | $1,624,000 | $1,624,000 | $1,346,000 |
| Current Assets | $114,095,000 | $66,383,000 | $40,013,000 | $84,409,000 |
| Other Current Assets | $342,000 | $211,000 | $245,000 | $205,000 |
| Restricted Cash | $1,346,000 | $0 | - | - |
| Prepaid Assets | $2,735,000 | $2,025,000 | $946,000 | $336,000 |
| Receivables | $155,000 | $108,000 | $442,000 | $678,000 |
| Other Receivables | $155,000 | - | - | - |
| Taxes Receivable | $0 | $108,000 | $442,000 | $678,000 |
| Cash Cash Equivalents And Short Term Investments | $109,517,000 | $64,039,000 | $38,380,000 | $83,190,000 |
| Cash And Cash Equivalents | $109,517,000 | $64,039,000 | $38,380,000 | $83,190,000 |
| Debt | ||||
| Total Debt | $1,974,000 | $8,487,000 | $11,693,000 | $12,395,000 |
| Long Term Debt And Capital Lease Obligation | $1,688,000 | $5,493,000 | $8,635,000 | $10,025,000 |
| Current Debt And Capital Lease Obligation | $286,000 | $2,994,000 | $3,058,000 | $2,370,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $70,104,000 | $15,163,000 | $178,676,000 | $180,080,000 |
| Total Non Current Liabilities Net Minority Interest | $54,590,000 | $5,565,000 | $170,869,000 | $172,134,000 |
| Other Non Current Liabilities | $29,000 | $72,000 | $87,000 | $-38,000 |
| Derivative Product Liabilities | $44,760,000 | $0 | - | - |
| Non Current Deferred Liabilities | $8,113,000 | $0 | - | - |
| Current Liabilities | $15,514,000 | $9,598,000 | $7,807,000 | $7,946,000 |
| Other Current Liabilities | $116,000 | $713,000 | $405,000 | $259,000 |
| Current Deferred Liabilities | $9,387,000 | $385,000 | $0 | - |
| Payables And Accrued Expenses | $3,083,000 | $2,395,000 | $2,407,000 | $3,799,000 |
| Payables | $182,000 | $1,210,000 | $1,042,000 | $2,151,000 |
| Accounts Payable | $182,000 | $1,210,000 | $1,042,000 | $2,151,000 |
| Equity | ||||
| Common Stock Equity | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Total Equity Gross Minority Interest | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Stockholders Equity | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Retained Earnings | $-292,156,000 | $-211,753,000 | $-159,962,000 | $-110,671,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $162,147,000 | $162,147,000 |
| Other | ||||
| Ordinary Shares Number | $51,902,614 | $20,161,072 | $19,505,119 | $19,505,119 |
| Share Issued | $51,902,614 | $20,161,072 | $19,505,119 | $19,505,119 |
| Tangible Book Value | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Invested Capital | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Working Capital | $98,581,000 | $56,785,000 | $32,206,000 | $76,463,000 |
| Capital Lease Obligations | $1,974,000 | $8,487,000 | $11,693,000 | $12,395,000 |
| Total Capitalization | $47,704,000 | $63,144,000 | $-123,730,000 | $-77,531,000 |
| Additional Paid In Capital | $339,854,000 | $274,895,000 | $36,231,000 | $33,139,000 |
| Capital Stock | $6,000 | $2,000 | $1,000 | $1,000 |
| Common Stock | $6,000 | $2,000 | $1,000 | $1,000 |
| Non Current Deferred Revenue | $8,113,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $1,688,000 | $5,493,000 | $8,635,000 | $10,025,000 |
| Current Deferred Revenue | $9,387,000 | $385,000 | $0 | - |
| Current Capital Lease Obligation | $286,000 | $2,994,000 | $3,058,000 | $2,370,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,642,000 | $3,111,000 | $1,937,000 | $1,777,000 |
| Current Accrued Expenses | $2,901,000 | $1,185,000 | $1,365,000 | $1,648,000 |
| Net PPE | $2,819,000 | $10,300,000 | $13,309,000 | $16,795,000 |
| Accumulated Depreciation | $-7,747,000 | $-6,231,000 | $-4,505,000 | $-3,039,000 |
| Gross PPE | $10,566,000 | $16,531,000 | $17,814,000 | $19,834,000 |
| Leases | $4,518,000 | $4,518,000 | $4,518,000 | $4,518,000 |
| Other Properties | $4,586,000 | $10,520,000 | $11,834,000 | $13,903,000 |
| Machinery Furniture Equipment | $1,462,000 | $1,493,000 | $1,462,000 | $1,413,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,832,000 | $-46,003,000 | $-44,833,000 | $-42,568,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-29,553,000 | $-45,562,000 | $-44,155,000 | $-38,543,000 |
| Cash Flow From Continuing Operating Activities | $-29,553,000 | $-45,562,000 | $-44,155,000 | $-38,543,000 |
| Operating Gains Losses | $30,088,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-279,000 | $-441,000 | $-678,000 | $-4,025,000 |
| Investing Cash Flow | $-243,000 | $-441,000 | $-678,000 | $-4,025,000 |
| Cash Flow From Continuing Investing Activities | $-243,000 | $-441,000 | $-678,000 | $-4,025,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $57,516,000 | $76,353,000 | $0 | $100,195,000 |
| Financing Cash Flow | $75,890,000 | $71,662,000 | $301,000 | $100,157,000 |
| Cash Flow From Continuing Financing Activities | $75,890,000 | $71,662,000 | $301,000 | $100,157,000 |
| Net Other Financing Charges | $14,833,000 | $-4,440,000 | $438,000 | - |
| Net Common Stock Issuance | $57,516,000 | $76,353,000 | $0 | - |
| Common Stock Issuance | $57,516,000 | $76,353,000 | $0 | - |
| Net Preferred Stock Issuance | - | - | $0 | $100,195,000 |
| Preferred Stock Issuance | - | - | $0 | $100,195,000 |
| Other | ||||
| Repayment Of Debt | $-111,000 | $-364,000 | $-322,000 | $-93,000 |
| End Cash Position | $111,757,000 | $65,663,000 | $40,004,000 | $84,536,000 |
| Beginning Cash Position | $65,663,000 | $40,004,000 | $84,536,000 | $26,947,000 |
| Changes In Cash | $46,094,000 | $25,659,000 | $-44,532,000 | $57,589,000 |
| Proceeds From Stock Option Exercised | $3,652,000 | $113,000 | $185,000 | $55,000 |
| Net Issuance Payments Of Debt | $-111,000 | $-364,000 | $-322,000 | $-93,000 |
| Net Long Term Debt Issuance | $-111,000 | $-364,000 | $-322,000 | $-93,000 |
| Long Term Debt Payments | $-111,000 | $-364,000 | $-322,000 | $-93,000 |
| Net PPE Purchase And Sale | $-243,000 | $-441,000 | $-678,000 | $-4,025,000 |
| Sale Of PPE | $36,000 | $0 | - | - |
| Purchase Of PPE | $-279,000 | $-441,000 | $-678,000 | $-4,025,000 |
| Change In Working Capital | $13,008,000 | $-1,331,000 | $-1,269,000 | $1,704,000 |
| Change In Other Working Capital | $14,119,000 | $-2,319,000 | $402,000 | $-888,000 |
| Change In Payables And Accrued Expense | $-223,000 | $1,699,000 | $-1,251,000 | $3,222,000 |
| Change In Accrued Expense | $805,000 | $1,531,000 | $-136,000 | $1,891,000 |
| Change In Payable | $-1,028,000 | $168,000 | $-1,115,000 | $1,331,000 |
| Change In Account Payable | $-1,028,000 | $168,000 | $-1,115,000 | $1,331,000 |
| Change In Prepaid Assets | $-888,000 | $-711,000 | $-420,000 | $-630,000 |
| Other Non Cash Items | $1,623,000 | $1,832,000 | $1,820,000 | $1,690,000 |
| Stock Based Compensation | $3,998,000 | $4,032,000 | $2,907,000 | $1,377,000 |
| Asset Impairment Charge | $494,000 | $0 | - | - |
| Depreciation Amortization Depletion | $1,639,000 | $1,696,000 | $1,678,000 | $878,000 |
| Depreciation And Amortization | $1,639,000 | $1,696,000 | $1,678,000 | $878,000 |
| Gain Loss On Investment Securities | $29,830,000 | - | - | - |
| Gain Loss On Sale Of PPE | $258,000 | $0 | - | - |
| Net Income From Continuing Operations | $-80,403,000 | $-51,791,000 | $-49,291,000 | $-44,192,000 |
Fetched: 2026-06-13